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We have continued our studies by detecting three markers of neuroendocrine
tumours of the lungs, including chromogranin A, NSE and synaptophysin, to
confirm the neuroendocrine origin of lung tumours and by examining the con-
tent of two anti-neoplastic cytokines, IL-2 and IL-12 in the tumours. The studies
were performed on paraffin sections of lung carcinoids (n = 13) and small cell
lung carcinomas (SCLC) (n = 15). Pronounced expression of all 3 markers of
neuroendocrine tumours was detected in most of the pulmonary carcinoids and
in 5/15 of SCLC. Co-expression of the two cytokines (IL-2 and IL-12) in tumour
cells was detected in 12/13 patients with lung carcinoid and expression of at
least one cytokine in 12/15 patients with SCLC. Significantly lower numbers of
cells immunoreactive to both cytokines were detected in SCLC as compared to
lung carcinoids. The studies have confirmed the literature data on the lowered
secretion of IL-2 in SCLC and extend the data by supplying information on the
expression of IL-12. The lowered expression of the two cytokines at the time of
diagnosis may represent a prognostic factor for survival in SCLC.
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INTRODUCTION
Activation of an anti-neoplastic immune response
in humans is generally known to involve 2 cytokines,
interleukin 2 (IL-2) and interleukin 12 (IL-12), but few
data are available on the production and secretion
of the cytokines by the tumour cells themselves [3, 4].
Inhibited secretion of IL-2 in SCLC was considered to
represent a prognostic index of survival in patients
with the tumour type [1]. Tissue expression of the
2 cytokines in neuroendocrine lung tumours remains
unknown. The present study therefore aimed at ex-
tending our previous studies on immunocytochemi-
cal detection of 2 cytokines, including IL-2 and
IL-12, in neuroendocrine tumours of the lungs of var-
ious degrees of histological malignancy and various
clinical patterns. The studies were preceded by im-
munocytochemical detection of 3 generally
recognised markers of pulmonary neuroendocrine
tumours (chromogranin A, NSE, synaptophysin) [6].
MATERIAL AND METHODS
The studies were performed on pulmonary carci-
noids (n = 13) and on small cell lung carcinomas
(n = 15) obtained from patients treated in the Inde-
pendent Specialist Public Hospital for Pulmonary Dis-
eases in Zakopane. Tumour samples obtained dur-
ing surgery were fixed in 10% buffered formalin and
embedded in paraffin blocks. Immunocytochemical
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studies according to ABC technique [2] employed
the following monoclonal antibodies: (a) rabbit anti-
-human chromogranin A antibody (b) mouse anti-
-human NSE antibody (c) mouse anti-human synap-
tophysin antibody (all from DAKO), (d) mouse anti-
human IL-2 antibody, (e) mouse anti-human IL-12
antibody (two latter from R&D Systems). Control re-
actions employed control sera of the respective spe-
cies (negative control) (DAKO) and reactive lymph
nodes (n = 3) from healthy controls (positive con-
trol). The intensity of the immunocytochemical re-
actions for neuroendocrine markers and both cytok-
ines was evaluated employing the semiquantitative
IRS scale, according to Remmele and Stegner [5],
taking into account the intensity of the colour reac-
tion and the number of positive cells. The final score
represented a product of the scores representing the
2 variables and ranged from 0 to 12 points (low re-
action: 1–2 points, average reaction: 3–4 points, in-
tense reaction: 6–12 points).
RESULTS AND DISCUSSION
In all the lung carcinoids (n = 13) and in 14/15
cases of SCLC the presence of chromogranin A,
NSE and synaptophysin was demonstrated. In the
carcinoids an intense reaction for all the 3 mar-
kers dominated (score: 6–12). In SCLC the reactions
for individual markers were more variable and in-
tense reactions were seen only in 5/15 cases (Fig. 1A).
Co-expression of IL-2 and IL-12 in tumour cells was
observed in 12/13 lung carcinoids and expression
of at least one cytokine was seen in 12/15 SCLC.
The cytokines demonstrated a cytoplasmic locali-
sation. As compared to the carcinoids, intensity of
the reactions for the two cytokines was generally
lower in SCLC (Fig. 1B). Immunoreactivity to both
cytokines was seen very rarely in mononuclear
blood cells (macrophages, lymphocytes) in tumour-
surrounding tissues. Our results demonstrated a
decreased expression of the 2 cytokines in SCLC
cells as compared to cells of lung carcinoids, which
confirmed some literature data on the lowered
secretion of IL-2 in SCLC, which was thought to
represent an independent prognostic index of sur-
vival in SCLC [1]. The earlier findings and our
present results have indicated also that cells of the
true tumour and not the mononuclear lymphoid
cells in the vicinity of tumour cells represent the
main source of the cytokines [4]. Detection of the
lowered expression of IL-2 and/or IL-12 in neoplas-
tic cells of neuroendocrine tumours may be regard-
ed as representing a prognostic factor, in line with
clinical observations and literature data on the
much higher malignancy of SCLC as compared to
that of lung carcinoids. This finding may also pro-
vide an indication for a more radical therapy. In ad-
Figure 1. Immunocytochemical localisation of chromogranin A (A) and IL-2 (B) in cancer cells of smallcell lung carcinoma. ABC method.
Original magn. × 400.
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dition, our studies have confirmed earlier reports
on the high sensitivity of studies on markers such
as chromogranin A, NSE and synaptophysin in the
diagnosis of the neuroendocrine origin of lung tu-
mours [4, 6].
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